Mayne Pharma’s Women’s Health Growth Fails to Offset Earnings Slide
Closing price · 2026-10-26: $2.48 · +1.22%
Mayne Pharma reported first-quarter revenue of approximately $96 million, down 2% from a year earlier, while underlying EBITDA fell 52% to approximately $5 million, as growth in Women’s Health was offset by weaker Dermatology sales and planned investment. Prescriptions rose across key Women’s Health products, and DistributeRx prescriptions more than doubled; the company also signed a five-year Australian licence for BLISSEL and reported legal settlements and a favourable appeal ruling, with its damages claim continuing.